New Phase 3b data on Lilly's Taltz and Zepbound used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Lilly's Foundayo significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
Lilly to showcase new retatrutide, Taltz and Zepbound data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FR?-targeting ADC at ESMO 2026
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
Lilly's Omvoh meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology Congress
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
